Literature DB >> 776312

A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients.

P Andrews, J N Hall, R P Snaith.   

Abstract

Phenothiazine drugs were withdrawn from 17 chronic schizophrenic in-patients, with a control group of 14 patients remaining on active medication. The trial was conducted under double blind conditions over a period of 42 weeks with weekly assessment of the patients by ward nurses. Of the placebo group 35% relapsed, relapse being related to the level of previous active medication.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 776312     DOI： 10.1192/bjp.128.5.451

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  6 in total

1.  A comparative trial of the decanoates of flupenthixol and fluphenazine.

Authors:  M Hamilton; I R Card; G G Wallis; M R Mahmoud
Journal:  Psychopharmacology (Berl)       Date:  1979-08-08       Impact factor: 4.530

2.  A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966-1993.

Authors:  Adil E Shamoo; Dianne N Irving; Patricia Langenberg
Journal:  Sci Eng Ethics       Date:  1997-10       Impact factor: 3.525

3.  A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.

Authors:  B Wistedt; A Jørgensen; D Wiles
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia.

Authors:  D J King; M Blomqvist; S J Cooper; M M Doherty; M J Mitchell; R C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

Review 6.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.